Kai Ding to Carboplatin
This is a "connection" page, showing publications Kai Ding has written about Carboplatin.
Connection Strength
0.083
-
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary. Gynecol Oncol. 2025 Dec; 203:158-164.
Score: 0.057
-
Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014 Apr; 133(1):11-5.
Score: 0.026